Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer

详细信息    查看全文

• 作者：Shanshan Yang (1)
  Huiyan Li (2)
  Yunduo Liu (1)
  Xiaoming Ning (3)
  Fanling Meng (1)
  Min Xiao (4)
  Deying Wang (5)
  Ge Lou (1)
  Yunyan Zhang (1)
  
• 关键词：Epithelial ovarian cancer ; MAC30 ; Immunohistochemistry ; Prognosis ; Lymph node metastasis
• 刊名：Medical Oncology
• 出版年：2013
• 出版时间：March 2013
• 年：2013
• 卷：30
• 期：1
• 全文大小：705KB
• 参考文献：1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277-00. CrossRef
  2. Rauh-Hain JA, Krivak TC, Del Carmen MG, Olawaiye AB. Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol. 2011;4(1):15-1.
  3. Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: status of the art at the end of the second millennium. Int J Gynecol Cancer. 2000;10(6):435-2. CrossRef
  4. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991;40(2):103-. CrossRef
  5. Katso RM, Manek S, Ganjavi H, Biddolph S, Charnock MF, Bradburn M, Wells M, Ganesan TS. Overexpression of H-Ryk in epithelial ovarian cancer: prognostic significance of receptor expression. Clin Cancer Res. 2000;6(8):3271-1.
  6. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519-9. CrossRef
  7. Murphy M, Pykett MJ, Harnish P, Zang KD, George DL. Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ. 1993;4(9):715-2.
  8. Kayed H, Kleeff J, Ding J, Hammer J, Giese T, Zentgraf H, Büchler MW, Friess H. Expression analysis of MAC30 in human pancreatic cancer and tumors of the gastrointestinal tract. Histol Histopathol. 2004;19(4):1021-1.
  9. Yan BY, Wang DW, Zhu ZL, Yang YH, Wang MW, Cui DS, Zhang H, Sun XF. Overexpression of MAC30 in the cytoplasm of oral squamous cell carcinoma predicts nodal metastasis and poor differentiation. Chemotherapy. 2010;56(6):424-. CrossRef
  10. Moparthi SB, Arbman G, Wallin A, Kayed H, Kleeff J, Zentgraf H, Sun XF. Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. Int J Oncol. 2007;30(1):91-.
  11. Zhang ZY, Zhao ZR, Adell G, Jarlsfelt I, Cui YX, Kayed H, Kleeff J, Wang MW, Sun XF. Expression of MAC30 in rectal cancers with or without preoperative radiotherapy. Oncology. 2006;71(3-):259-5. CrossRef
  12. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, TeLinde RW, editors. Blaustein’s pathology of the female genital tract. 5th ed. New York: Springer; 2002. p. 791-04.
  13. Moparthi SB, Arbman G, Wallin A, Kayed H, Kleeff J, Zentgraf H, Sun XF. Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. Int J Oncol. 2007;30(1):91-.
  14. Staging announcement. FIGO Cancer Committee. Gynecol Oncol 1986;25(3):383-.
  15. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms (review). Nat Rev Cancer. 2005;5(5):355-6. CrossRef
  16. Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: status of the art at the end of the second millennium. Int J Gynecol Cancer. 2000;10(6):435-2. CrossRef
  17. Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, Lagasse LD, Karlan BY. Pattern of lymph node metastasis in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol. 2001;80(1):56-1. CrossRef
  18. Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, Pomel C, Lhommé C, Duvillard P, Castaigne D. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003;197(2):198-05. CrossRef
  19. Di Re F, Baiocchi G, Fontanelli R, Grosso G, Cobellis L, Raspagliesi F, Di Re E. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastasis. Gynecol Oncol. 1996;62(3):360-. CrossRef
  20. Onda T, Yoshikawa H, Yokota H, Yasugi T, Taketani Y. Assessment of metastasis to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Cancer. 1996;78(4):803-. CrossRef
  21. Benedetti-Panici P, Greggi S, Maneschi F, Scambia G, Amoroso M, Rabitti C, et al. Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer. Gynecol Oncol. 1993;51(2):150-. CrossRef
  22. Petru E, Lahousen M, Tamussino K, Pickel H, Stranzl H, Stettner H, Winter R. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol. 1994;170(2):656-2.
  23. Wu PC, Qu JY, Lang JH, Huang RL, Tang MY, Lian LJ. Lymph node metastasis of ovarian cancer: a preliminary survey of 74 cases of lymphadenectomy. Am J Obstet Gynecol. 1986;155(5):1103-.
  24. Zhao ZR, Zhang LJ, He XQ, Zhang ZY, Zhang F, Li F, Pei YB, Hu YM, Wang MW, Sun XF. Significance of mRNA and protein expression of MAC30 in progression of colorectal cancer. Chemotherapy. 2011;57(5):394-01. CrossRef
  25. Malhotra K, Luehrsen KR, Costello LL, Raich TJ, Sim K, Foltz L, Davidson S, Xu H, Chen A, Yamanishi DT, Lindemann GW, Cain CA, Madlansacay MR, Hashima SM, Pham TL, Mahoney W, Schueler PA. Identification of differentially expressed mRNAs in human fetal liver across gestation. Nucleic Acids Res. 1999;27(3):839-7. CrossRef
  26. Atalay A, Crook T, Ozturk M, Yulug IG. Identification of genes induced by BRCA1 in breast cancer cells. Biochem Biophys Res. 2002;299(5):839-6. CrossRef
  27. Monteiro AN. BRCA1: the enigma of tissue-specific tumor development. Trends Genet. 2003;19(6):312-. CrossRef
  28. Rosen EM, Fan S, Pestell RG, Goldberg ID. BRCA1 gene in breast cancer. J Cell Physiol. 2003;196(1):19-1. CrossRef
  29. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene. 2001;20(18):2225-4. CrossRef
  
• 作者单位：Shanshan Yang (1)
  Huiyan Li (2)
  Yunduo Liu (1)
  Xiaoming Ning (3)
  Fanling Meng (1)
  Min Xiao (4)
  Deying Wang (5)
  Ge Lou (1)
  Yunyan Zhang (1)
  
  1. Department of Gynecology, The Affiliated Tumor Hospital of Harbin Medical University, Baojian Road 6, Nangang District, Harbin, 150081, China
  2. Department of Radiotherapy, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China
  3. Department of Pathology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China
  4. Department of Breast Surgery, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China
  5. Department of Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
  

文摘

Meningioma-associated protein (MAC30), first described to be overexpressed in meningiomas, exhibits altered expression in certain human tumors. The definite role of MAC30 is not clear now, and few studies have documented the value of MAC30 in epithelial ovarian cancer (EOC). The aim of this study was to investigate the expression of MAC30 in EOC and to evaluate its clinical significance in patients with EOC. A total of 266 patients with EOC who undergone complete cytoreductive surgery from November 2003 to September 2006 were eligible for this study. The expression of MAC30 in epithelial ovarian tumor tissues was examined immunohistochemically. High expression of MAC30 was observed in 66.17?% of EOC. The high MAC30 expression group had more advanced stages, poorer histological grade, lymph node metastasis, and recurrence than those with low MAC30 expression. Moreover, the presence of lymph node metastasis was significantly associated with MAC30 expression (OR 2.888, 95?% CI 1.428-.838, P?=?0.003). In addition, it was also shown that high MAC30 expression significantly correlated with poorer overall survival and progression-free survival (both P?<?0.001). Multivariate Cox regression analysis revealed that MAC30 expression status was an independent prognostic factor for both overall survival and progression-free survival (P?=?0.001 and P?=?0.002, respectively) of patients with EOC. Our study provides evidence that patients with expression of MAC30 in EOC have high malignant potential, and MAC30 may serve as a new molecular marker to predict the lymph node metastasis and prognosis of patients with EOC in the clinic.